Roberto A. S. V. Mazetto

Roberto A. S. V. Mazetto

Auto-generated profile, based on publicly available information

Roberto A. S. V. Mazetto

Universidade do Estado do Amazonas, Escola Superior de Ciências da Saúde, Departamento de Medicina, Manaus AM, Brazil

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 August 2024 in European Journal of Haematology
Verified
Journal Article
Closed access
RMRoberto A. S. V. Mazetto
Roberto A. S. V. Mazetto
SMSarah O. N. Monteiro
Sarah O. N. Monteiro
EBElísio Bulhões
Elísio Bulhões
MDMaria L. R. Defante
Maria L. R. Defante
VAVanio L. J. Antunes
Vanio L. J. Antunes
CGCamila Guida
Camila Guida

9 July 2024 in Journal of Interventional Cardiac Electrophysiology
Verified
Journal Article
Closed access
PDF file
RMRoberto Augusto Mazetto
Roberto Augusto Mazetto
VAVânio Antunes
Vânio Antunes
EBElísio Bulhões
Elísio Bulhões
MDMaria Defante
Maria Defante
CBCaroline Balieiro
Caroline Balieiro
CGCamila Guida
Camila Guida

19 March 2025 in Arquivos de Neuro-Psiquiatria
Verified
Journal Article
Open access
PDF file
LNLuis O. S. Nogueira
Luis O. S. Nogueira
RMRoberto A. S. V. Mazetto
Roberto A. S. V. Mazetto
MDMaria L. R. Defante
Maria L. R. Defante
VAVânio L. J. Antunes
Vânio L. J. Antunes
OGOcílio Ribeiro Gonçalves
Ocílio Ribeiro Gonçalves
HFHenrique B. Ferraz
Henrique B. Ferraz
Background Recent research on Parkinson's disease (PD) therapy has highlighted glucagon-like peptide 1 (GLP-1) agonists as potential therapeutic agents. However, recent randomized controlled trials (RCTs) have shown mixed results regarding the use of this medication. Objective To perform a meta-analysis comparing GLP-1 agonists with placebo or standard PD treatment in adult PD patients. Methods We systematically searched the PubMed, Embase and Cochrane Central databases. The efficacy outcomes were assessed through the Movement Disorder Society Unified Parkinson Disease Rating Scale (MDS-UPDRS) and the 39-item Parkinson's Disease Questionnaire (PDQ-39). We also assessed adverse events. Dichotomous data were compared using the risk ratio (RR), and continuous endpoints were pooled using the mean difference (MD). Results We included 4 RCTs, with a total of 514 patients. In every study, the Hoehn and Yahr stage was < 3. The pooled analysis demonstrated that the use of GLP-1 agonists was not associated with an improvement in the scores on parts I, II, III, and IV of the MDS-UPDRS at 6 and 12 months of follow-up. Neither did quality of life (PDQ-39) show significant differences among the groups, and a higher risk of gastrointestinal adverse events and weight loss was observed with the use of GLP-1 agonists. A subgroup analysis further confirmed the lack of clinical benefits of the intervention regarding all of these efficacy outcomes, and the intervention also significantly reduced result heterogeneity. Conclusion In 1 year, GLP-1 agonists failed to improve motor and non-motor features of PD. Additional high-quality studies are needed to draw more robust conclusions about this treatment.

30 December 2024 in Journal of Interventional Cardiac Electrophysiology
Verified
Journal Article
Closed access
PDF file
EBElísio Bulhões
Elísio Bulhões
RMRoberto A. S. V. Mazetto
Roberto A. S. V. Mazetto
AVAntunes L. Vanio
Antunes L. Vanio
MDMaria L. R. Defante
Maria L. R. Defante
LFLuanna Feitoza
Luanna Feitoza
HHHenry Huang
Henry Huang

8 February 2026 in Catheterization and Cardiovascular Interventions
Verified
Journal Article
Closed access
VOVinícius Martins Rodrigues Oliveira
Vinícius Martins Rodrigues Oliveira
LBLucas M. Barbosa
Lucas M. Barbosa
PSPedro Antônio de Sousa
Pedro Antônio de Sousa
ALAna Paula Duarte Lima
Ana Paula Duarte Lima
MAMaria Antonia Cruz Akabane
Maria Antonia Cruz Akabane
LTLudimilla Pereira Tartuce
Ludimilla Pereira Tartuce